Limited Returns For Roche And AstraZeneca In Lung Cancer As NICE Restricts Tarceva And Iressa
This article was originally published in The Pink Sheet Daily
NICE’s decision to severely restrict second-line use of Roche’s Tarceva and AstraZeneca’s Iressa will not help distance the drugs sufficiently from a chasing pack, including Boehringer’s Giotrif.
You may also be interested in...
It’s become commonplace to see monthly pricing of $10,000 for new cancer drugs, but with competition in mind Boehringer takes a conservative approach with its non-small-cell lung cancer drug Gilotrif (afatinib).
The U.K.’s National Institute for Health and Clinical Excellence is asking for a further cost-effectiveness analysis of Roche’s Tarceva to weigh against the cost effectiveness of AstraZeneca’s Iressa.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.